Research programme: peptide-carrier therapeutics - Phylogica/Roche

Drug Profile

Research programme: peptide-carrier therapeutics - Phylogica/Roche

Alternative Names: Cell-penetrating peptides - Phylogica/Roche; Phylomer® carrier peptides - Phylogica/Roche

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Phylogica; Roche
  • Class Drug conjugates; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders; Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders in Australia
  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in Australia
  • 23 May 2011 Early research in Neurological disorders in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top